Steven Powell

12PUBLICATIONS
127CO-AUTHORS
Tumour immunologyMolecular targetsAllergyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 29, 2026
A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors.

|Oct 07, 2026
Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

|Jun 22, 2026
Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors.

|Jan 15, 2026
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Daniel R Carrizosa, Michael Rothe, Pam K Mangat

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Oct 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Francis P Worden, Evan Pisick, Michael Rothe

Pageof 2

Frequent Collaborators

5 joint publications

Richard L Schilsky

5 joint publications

Abigail Gregory

5 joint publications

Susan Halabi

5 joint publications

Dominique C Hinshaw